NFKB1 and breast carcinoma: In addition, LY294002 and NF-κB silencing also inhibited stemness significantly, indicating that targeting PI3K/AKT/NF-κB pathway is emerged as a promising approach to kill CSCs and consequently surmount MDR in breast cancers.